Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Aug 2018
Meta AnalysisSystematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.
There are limited data to inform positioning of agents for treating moderate-severe Crohn's disease (CD). ⋯ Indirect comparisons suggest that infliximab or adalimumab may be preferred first-line agents, and ustekinumab a preferred second-line agent, for induction of remission in patients with moderate-severe CD. Head-to-head trials are warranted.